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Abstract  
Bovine papillomavirus (BPV) types 1 and 2 play an important role in the pathogenesis of 
equine sarcoids (ES), the most common cutaneous tumour affecting horses. MicroRNAs 
(miRNAs), small non-coding RNAs that regulate essential biological and cellular 
processes, have been found dysregulated in a wide range of tumours. The aim of this 
study was to identify miRNAs associated with ES. Differential expression of miRNAs 
was assessed in control equine fibroblasts (EqPalFs) and EqPalFs transformed with the 
BPV-1 genome (S6-2 cells). Using a commercially available miRNA microarray, 492 
mature miRNAs were interrogated. In total, 206 mature miRNAs were differentially 
expressed in EqPalFs compared with S6-2 cells. Aberrant expression of these miRNAs in 
S6-2 cells can be attributed to the presence of BPV-1 genomes. Furthermore, we confirm 
the presence of 124 miRNAs previously computationally predicted in the horse. Our data 
supports the involvement of miRNAs in the pathogenesis of ES.  						
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Introduction  
Bovine papillomaviruses (BPVs) are non-enveloped double-stranded DNA 
epitheliotropic viruses that give rise to papillomas, fibropapillomas and/or bladder cancer 
in cattle.1 – 4 It is also well established that BPVs (type 1 and less commonly type 2) are 
involved in the pathogenesis of equine sarcoid tumours (ES).5 – 7 Sarcoids are the most 
common cutaneous tumours in horses and they are described as locally invasive 
fibroblastic neoplasia of equine skin.8,9 Sarcoids can present in a range of clinical forms 
from mild to malignant and currently therapeutic options are limited. 9,10 In sarcoids, the 
viral DNA is detected primarily in fibroblasts11 – 14 although BPV-1 genomes can be 
detected within the epidermis, suggesting a more complex aetiopathogenesis.15 Whilst 
infection with BPV-1/-2 has been implicated as an essential factor in sarcoid 
development, the mechanisms by which BPV infection contributes to tumorigenesis 
remain unclear. The BPV-1/-2 genome encodes several early (E1, E2, E5, E6 and E7) and 
two late genes, L1 and L2, which code for capsid proteins. BPV-1/-2 E5 and E6 are 
considered the major oncogenes in ES.16 E5 induces tumorigenic transformation by 
strongly and specifically binding to its cellular target, platelet-derived growth factor-β 
receptor (PDGF β -R) tyrosine kinase in a ligand-independent manner.17 Activation of 
PDGF𝛽-R of the dermal fibroblasts results in mitogenesis in nearby epithelial cells,18 
contributing to the pseudoepitheliomatous hyperplasia that is typically observed in BPV-
infected lesions. BPV-1/-2 E6 degrades bovine p5319,20 and presence of BPV genomes in 
sarcoids induces mis-localization of p53 by an unknown mechanism.21 
In this study, we describe the differences in microRNA (miRNA) expression that may 
lead to BPV-1 induced tumorigenesis. MicroRNAs (miRNAs) are 18–23 nucleotide, 
single-stranded RNA molecules that regulate gene expression at the post-transcriptional 
level22 and are expressed in all metazoan eukaryotes. Through imperfect base-pairing to 
target mRNA, most commonly in the 3′-untranslated region (UTR), miRNAs inhibit 
mRNA translation by causing deadenylation and/or degradation of the target mRNA.23 
miRNAs participate in the regulation of the cell cycle, proliferation/differentiation, 
apoptosis and senescence, and dysfunctional expression of miRNAs has been linked to 
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malignancies.24–30 Depending on the nature of their targets, miRNAs can function as 
oncogenes (oncomiRs) or tumour suppressors.31  
Numerous studies show upregulation of oncogenic miRNAs and downregulation of 
tumour-suppressive miRNAs in human papillomavirus (HPV) cervical cancer biopsies 
and in cervical cancer lines in comparison with controls.32 – 38 In HPV-induced cancer, 
numerous miRNAs have been identified as oncomiRs. Similarly, miRNAs including let-7 
family, miR-7, miR-17-5p, miR-125, miR-218 and miR-433 have been reported to 
function as tumour suppressors.39,40 In HPV-induced cancers, the expression of E6 and E7 
has been linked to aberrant expression of miRNAs leading to alteration of p53 and pRB 
pathways and associated with carcinogenic transformation.33,39,41  
In vitro changes to the equine fibroblast transcriptome induced by BPV-1 infection have 
been investigated previously by microarray expression pro ling.42 The results 
demonstrated altered expression of genes involved in a range of processes including 
immunity and inflammation, cell adhesion, motility as well as cell cycle/cell proliferation 
and apoptosis.42 To gain a better understanding of the molecular pathogenesis associated 
with BPV-1-induced tumorigenesis in sarcoids, the aim of this study was to identify 
cellular miRNAs that are differentially expressed in BPV-1-transformed equine 
fibroblasts. This was achieved by assessing differences in miRNA expression in normal 
equine fibroblasts (EqPalFs) compared with equine fibroblasts transformed with BPV-1 
genomes, S6-2 cells. Our data identify for the first time, cellular miRNAs associated with 
BPV-1 transformation of equine cells. 
Materials and methods  
Equine fibroblast cell culture  
Equine primary fibroblasts and BPV-1 trans- formed cells (S6-2) are well characterized 
cell lines that have been described previously.21 All cells were maintained in culture in a 
37∘C humidified atmosphere with 5% CO2, in culture media containing High Glucose 
Dulbecco’s Modified Eagles medium with Pyruvate (DMEM-GlutaMAXTM ) (Gibco®, 
Life Technologies, Paisley, UK), 10% of heat inactivated foetal bovine serum (Gibco®), 
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penicillin – streptomycin (10 000 U mL−1 ) (Gibco®) and Fungizone® Antimycotic 
(Gibco®). Cells were routinely tested for mycoplasma and were consistently negative. 
Local ethical approval was granted to conduct this study.  
miRNA microarray  
Total RNA was isolated from EqPalFs and S6-2 cells at low passage (<10) using Trizol® 
Reagent (Life Technologies) as per the manufacture’s advice, vortexed and kept at 
−80∘C until further use. Quality of RNA was assessed using a 2100 Bioanalyzer (Agilent 
Technologies, Stockport, UK). All samples had an RNA integrity number (RIN value) of 
10.0. A sample of 750ng of total RNA from the cell lines was fluorescently labelled, 
using the miRCURY LNATM microRNA Hi-Power Labelling Kit, Hy3TM/Hy5TM 
(Exiqon, Vedbaek, Denmark) following the manufacturer’s instructions. The query 
samples (EqPalFs and S6-2 cells) were labelled using Hy3 whereas the reference sample 
(a pooled sample of RNA from both cell lines) was dyed using Hy5. Samples were run on 
a miRCURY LNATM microRNA Array 7th Gen (Exiqon). This array comprises 2164 
probes that contain human and viral miRNA sequences together with predicted equine 
microRNA sequences derived from miRBase 19.0.43  
The slides were scanned using the Agilent G2565BA Microarray Scanner System 
(Agilent Technologies) and the image analysis was carried out using the ImaGene® 9 
miRCURY LNATM microRNA Array Analysis So ware (Exiqon). Pre-processing of the 
data included background subtraction (Normexp with o set value 10) and normalization 
using the global lowess regression algorithm. Moderated t-statistics were applied to 
determine differential expression of microRNAs between EqPalFs and S6-2 cells. 
Following this, the Benjamini and Hochberg multiple testing adjustment method was 
applied to the P values. P values of 0.05 or lower were considered to be statistically 
significant. Calculations were performed with R/Bioconductor using the limma package.  
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Validation of miRNA expression  by quantitative real-time PCR (qRT-PCR)  
A total of 11 miRNAs were initially selected for validation of the microarray results 
based on fold-change (±2-fold), signal intensity (7.5–14.5) and biological significance 
(i.e. having previously been reported to be dysregulated in HPV-related disease and/or 
cancer). miRNAs were quantified using SYBR green; however, due to problems with 
non-specific amplification and low efficiency for some primer sets, a panel of miRNAs 
were examined using Taqman qRT-PCR.  
Total RNA from each cell line was treated with DNase (DNA-freeTM Kit, Life 
Technologies) and quantified with QubitTM RNA Assay Kits (Invitrogen, Life 
Technologies). Using 10 – 300 ng of total RNA, cDNA was synthesized using the Mir-
XTM-miRNA First-strand synthesis kit (Takara Bio Europe, St Germaine en Laye, 
France) or stem-loop primers from TaqMan® MicroRNA Reverse Transcription Kit (Life 
Technologies). Primers used for amplification were supplied as part of the kits with the 
exception of the 5′ primers for SYBR green and these are listed in Table 1. Quantification 
of miRNAs was performed with SYBR® qRT-PCR technology (Takara Bio Europe, St 
Germaine en Laye, France) or TaqMan MicroRNA Assays (Life Technologies) following 
the manufacturer’s advice. The protocol was optimized by decreasing the amount of 
cDNA per reaction to 1μL, decreasing the concentration of the primers to 5 pmol per 
reaction for the SYBR green kit and increasing the amount of cDNA per reaction to 2 μL 
for the Taqman kit. Each amplification reaction was performed in triplicate and the 
average Ct value was used for subsequent analysis. Expression of each miRNA was 
normalized using U6 and differential expression was calculated using the ΔΔCt 
method.44 – 46  
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Table 1. List of 5’ primer sequences used for qRT-PCR validation of 
microRNAs 
  
Annotation		 SYBR	green	5'	primer	 miRBase	accession	
eca-miR-106a/17	 CAAAGTGCTTACAGTGCAGGTAG	 MIMAT0013194	
eca-miR-127	(hsa-miR-127-3p)	 TCGGATCCGTCTGAGCTTGGCT	 MIMAT0013126		
eca-miR-132	(hsa-miR-132-3p)	 TAACAGTCTACAGCCATGGTCG	 MIMAT0013021		
eca-miR-143	 TGAGATGAAGCACTGTAGCTC	 MIMAT0013063	
eca-miR-15b	 TAGCAGCACATCATGGTTTACA	 MIMAT0012954		
eca-miR-181a-5p	 AACATTCAACGCTGTCGGTGAGT	 MIMAT0013178		
eca-miR-23b	 ATCACATTGCCAGGGATTACC	 MIMAT0013113		
eca-miR-409-3p	 GAATGTTGCTCGGTGAACCCCT	 MIMAT0013151	
hsa-let-7b-5p		 TGAGGTAGTAGGTTGTGTGGTT	 MIMAT0000063	
hsa-miR-4732-5p	 TGTAGAGCAGGGAGCAGGAAGCT	 MIMAT0019855	
hsa-miR-663a	 AGGCGGGGCGCCGCGGGACCGC	 MIMAT0003326	
 
Results  
In this study we used microarray analysis to identify miRNAs that are differentially 
expressed in BPV-1 transformed EqPalF cells (S6-2 cells) compared with control 
parental EqPalF cells. The microarray comprised human and viral miRNA sequences as 
well as computationally predicted equine miRNA sequences. A total of 402 unique short 
RNA sequences were identified as potential miRNAs in equine fibroblasts, of which 124 
sequences match the previously predicted miRNAs in the horse,47 confirming that these 
miRNAs are expressed within the horse genome. The list of 124 miRNAs is presented as 
Table S1, Supporting Information.  
Of the 2164 miRNA probes on the microarray, 492 had a signal above the background 
thresh- old level in both cell lines. Of these, 22 were repeated sequences, 1 repeated 
annotation, 12 small nucleolar RNAs, 9 synthetic microRNAs and 27 non-papilloma viral 
sequences. Furthermore, 19 false positives were removed from the analysis, as these 
probes can display atypical signal patterns (Exiqon).  
Applying moderated t-statistics with a multiple test correction, 206 microRNA candidates 
were identified to be differentially expressed between S6-2 cells and EqPalF cells (P < 
0.05). Over two thirds (144 miRNAs, 70%) of the differentially expressed miRNAs were 
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downregulated in the S6-2 cells and 62 (30%) were upregulated (Fig. 1). The top 10 
upregulated and downregulated miRNA candidates on the basis of fold change are listed 
in Table 2. All raw and normalized miRNA expression data are available from the 
NCBI’s Gene Expression Omnibus48 and are accessible through GEO series accession 
number GSE73937 (http://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc = GSE73937).  
 
Figure 1. Heat map representing differences in expression top 50 microRNAs. S-62-
1 to 3 are the three replicates of BPV transformed equine fibroblasts, EqPalF-1 to 3 
are the three replicates of equine primary fibroblasts. The clustering was performed 
on all samples using the complete-linkage method together with the Euclidean 
distance measure, and on the top 50 miRNA with highest standard deviation. The 
normalized log ratio values have been used for the analysis. Red represents lower 
expression and green represents higher expression of microRNAs of the samples 
compared to the control channel of the microarray (a pooled sample of both cell 
lines). 
 
	 8	
Table 2. Top 10 down and 10 upregulated microRNAs in S6-2 cells (in vitro BPV-1 
transformed equine primary fibroblasts) compared to EqPalFs (equine primary 
fibroblasts) ranked on fold change 
 
To validate the S6-2 versus EqPalFs microarray results, 11 differentially expressed 
miRNAs were assessed by qRT-PCR using RNA prepared from three biological 
replicates of the same cell lines. The miRNAs were chosen based on the following 
thresholds advised by Exiqon: absolute fold-change of ≥2, microarray signal intensity 
between 7.5 and 14.5 and biological significance, i.e. previously shown to be implicated 
in HPV-associated cancer. Real-time quantification showed that 6 of the 11 microRNAs 
tested showed significantly higher expression in EqPalF than S6-2 cells, as expected (let-
7b, miR-17, miR-23b, miR-132, miR-143 and miR-181a) (Fig. 2), confirming the results 
from the microarray. The Pearson’s correlation coefficient between microarray and qPCR 
data was 0.68 (Fig. 3). One miRNA (miR-663a) showed no significant difference, whilst 
two miRNAs had an inverse expression pattern to the microarray data (miR-15b and 
miR-127). Two miRNAs (miR-409 and miR-4732) could not be quantified due to low 
efficiency and/or non-specific amplification.  
Annotation	
Fold	
change	 RNA	sequence	probe	
Adjusted	P	
value	
eca-miR-127	 -4.35	 UCGGAUCCGUCUGAGCUUGGCU	 1.34	x	10-8	
hsa-miR-4732-5p	 -2.94	 UGUAGAGCAGGGAGCAGGAAGCU	 1.34	x	10-8	
eca-miR-132	 -2.78	 UAACAGUCUACAGCCAUGGUCG	 2.79	x	10-7	
eca-miR-181a	 -2.38	 AACAUUCAACGCUGUCGGUGAGU	 3.65	x	10-8	
eca-miR-409-3p	 -2.27	 GAAUGUUGCUCGGUGAACCCCU	 5.36	x	10-7	
hsa-miR-663a	 -2.17	 AGGCGGGGCGCCGCGGGACCGC	 9.81	x	10-8	
hsa-miR-3158-5p	 -2.04	 CCUGCAGAGAGGAAGCCCUUC	 2.79	x	10-7	
eca-miR-15b	 -2.00	 UAGCAGCACAUCAUGGUUUACA	 2.20	x	10-7	
eca-miR-106a/	eca-miR-17	 -1.96	 UCAAAUGCUCAGACUCCUGUGGU	 3.70	x	10-7	
eca-miR-199a-3p/	eca-miR-199b-3p	 -1.96	 GGUCCAGAGGGGAGAUAGGUUC	 5.02	x	10-7	
eca-miR-1902	 +1.52	 AGAGGUGCAGUAGGCAUGACUU	 1.1	x	10-5	
hsa-miR-493-5p	 +1.48	 UUGUACAUGGUAGGCUUUCAUU	 8.20	x	10-6	
hsa-miR-4484	 +1.42	 AAAAGGCGGGAGAAGCCCCA	 1.28	x	10-5	
hsa-miR-1285-3p	 +1.41	 UCUGGGCAACAAAGUGAGACCU	 1.54	x	10-5	
hsa-miR-3121-5p	 +1.40	 ACUUUCCUCACUCCCGUGAAGU	 8.04	x	10-6	
hsa-miR-639	 +1.38	 AUCGCUGCGGUUGCGAGCGCUGU	 1.70	x	10-4	
eca-miR-193b	 +1.36	 AACUGGCCCACAAAGUCCCGCU	 1.46	x	10-5	
hsa-miR-4742-3p	 +1.32	 UCUGUAUUCUCCUUUGCCUGCAG	 6.63	x	10-5	
eca-miR-1248	 +1.29	 UCCUUCUUGUAUAAGCACUGUGCUAAA	 3.94	x	10-5	
eca-miR-99a	 +1.27	 AACCCGUAGAUCCGAUCUUGUG	 5.15	x	10-5	
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Figure 3.  Correlation between results of microarray and qRT-PCR. The differential 
expression of miRNAs in control equine fibroblasts (EqPalF) and BPV-1 transformed 
equine fibroblasts (S6-2 cells) was calculated by microarray (X axis, S6-2/EqPalF ratio) 
and qRT-PCR (y axis, log2 fold-change of S6-2 vs EqPalF). 
 
Discussion  
Research and interest in the role of microRNAs in virus–host interactions has increased 
in recent years.49 – 51 Viruses are able to remodel cellular miRNA expression networks 
impacting on the pathogenesis of virally induced cancers.26,28,52–54 To date, there are few 
studies on equine miRNAs and, to the best of our knowledge, no studies have 
investigated the impact of viral infection on miRNA expression in equine cells.  
MicroRNAs are highly conserved across species55 and phylogenetic conservation of the 
mature sequence was utilized in the first report on equine miRNAs. Using an integrated 
comparative genomic approach to the human genome and other animal genomes, a total 
of 354 mature sequences of miRNA candidates were computationally predicted in the 
horse.47 In our study, we were able to confirm that 124 of these predicted miRNAs are 
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indeed expressed within the equine genome.  
In addition, we show that 206 microRNA candidates are differentially expressed in BPV-
1 trans- formed equine cells compared with control equine cells. Pathway analysis to 
group the candidate miRNAs on the basis of functional processes was attempted; 
however, due to the limited transcriptomic dataset available42 and the low number of 
microRNAs present in the Ingenuity Pathway Analysis database, this method could not 
provide information on the pathways and networks involved 
(http://www.ingenuity.com/products/ipa).  
An interesting observation in our study was that most of the differentially expressed 
miRNAs (70%) were downregulated in transformed cells, several of which have also 
been shown to be dysregulated in HPV-induced cancers (Table 3).27–29,34,53,54,59  
Table 3. List of 25 miRNAs found dysregulated in this study and in HPV induced 
cancers 
miRNA	 Source	
let-7d	 Zheng	and	Wang,	201126;	Honnegger	et	al.	201556	
miR-100	 Wang	et	al.,	201454	
miR-10b		 Witten	et	al.,	201057;	Li	et	al.,	201127	
miR-125b		 Witten	et	al.,	201057;	Li	et	al.,	201127;	Nuovo	et	al.	201058	
miR-127		 Li	et	al.,	201127;	Zheng	and	Wang,	201128	
miR-133a		 Zheng	and	Wang,	201128		
miR-143	 Zheng	and	Wang,	201128;	Lajer	et	al.,	201234	
miR-145	 Lajer	et	al.,	201234	
miR-155		 Wald	et	al.,	201129	
miR-15a	 Zheng	and	Wang,	201128;	Lajer	et	al.,	201234	
miR-181a	 Wald	et	al.,	201129;	Wang	et	al.,	201454	
miR-181b	 Wald	et	al.,	201129	
miR-183	 Wang	et	al.,	201454	
miR-191*		 Zheng	and	Wang,	201128	
miR-221	 Wald	et	al.,	201129	
miR-222	 Wald	et	al.,	201129	
miR-23b	 Au	Yang	et	al.,	201126	
miR-24	 Wang	et	al.,	201454	
miR-27a	 Wang	et	al.,	201454	
miR-29a		 Li	et	al.,	201127;	Zheng	and	Wang,	201128	
miR-29c	 Wang	et	al.,	201454	
miR-30b		 Zheng	and	Wang,	201128	
miR-31	 Wang	et	al.,	201454	
miR-378	(422b)		 Zheng	and	Wang,	201128	
miR-455-3p	 Zheng	and	Wang,	201128;	Wang	et	al.,	201454	
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We successfully validated differential expression of 6 of 11 selected microRNAs (let-7b, 
miR-17, miR-23b, miR-132, miR-143, miR-181a) by quantitative RT-PCR. For two of 
the selected miRNAs we were unable to optimize the PCR reactions. miR-663a was 
shown to be significantly down- regulated by microarray analysis (fold change of −2.17); 
however, qPCR showed no difference in expression. Similarly, we were unable to 
validate the results for miR-15b and miR-127, which showed an inverse relationship by 
quantitative PCR. Whilst it has been shown that there is generally an excellent correlation 
between different total RNA extraction methods, there are a few miRNAs whose levels 
do not correlate between microarray and qPCR measurements.60  
In our study we observed that let-7b was significantly downregulated by BPV-1 
expression. In most human cancers, let-7b is considered to function as a tumour 
suppressor, inhibiting cancer cell proliferation and tumour growth.61 – 63 miRNAs from the 
let-7 family reduce cancer cell proliferation and tumour development by controlling the 
expression of a number of oncogenes, such as RAS and MYC.64 Let-7b has been shown 
to be downregulated in a range of cancers including HPV-induced cancers.62 Because let-
7b can function as a tumour suppressor, the downregulation of let-7b expression by BPV-
1 may contribute to the tumoral transformation of equine cells.  
Our study showed that miR-17 expression was also significantly downregulated in S6-2 
cells. miR-17 has been reported to promote cell proliferation, to reduce apoptosis and to 
participate in the immune response to HPV-induced cervical cancer.64 Zheng and Wang28 
and Li et al.59 have shown that miR-17 is upregulated in HPV 16 cervical tissues when 
compared with normal cervix. Our observed downregulation suggests that miR-17 can be 
modulated differently by distinct papillomaviruses.  
Analysis of miR-23b by qPCR demonstrated that this miRNA is also downregulated. 
miR-23b  has been shown to be involved in a wide range of cellular processes65,66 and 
aberrant expression of miR-23b has been reported in many types of cancers.67 – 69 Zhang et 
al.70 showed that miR-23b suppressed invasion and metastasis both in vitro and in vivo. 
HPV-16 E6 protein has been reported to downregulate expression of miR-23b via 
expression of urokinase type plasminogen activator (uPA).26 We have previously shown 
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that BPV-1 oncogene E5 and E6 induced invasion of equine cells42 and the 
downregulation of miR-23b by viral oncogenes may represent a pathway by which this 
occurs. miR-23 has been predicted to be encoded within a chromosomal region linked to 
the development of sarcoids.71  
e results from microarray and qRT-PCR show that miR-132 is significantly 
downregulated in S6-2 cells compared with EqPalF cells. This miRNA has been shown to 
be upregulated in HPV cervical cancer72 and gastric cancer.73 However, in other types of 
cancer such as breast cancer, osteosarcoma and pancreatic cancer74-76 miR-132 has been 
found to be downregulated.  
miR-143 is downregulated by BPV-1. miR-143 has been shown to be dysregulated by 
HPV-16  leading to an inability to stop proliferation in cervical cancer via the p53 
pathway and it has been claimed to be an anti-tumoral miRNA.28,34 It is a miRNA that has 
consistently been shown to be downregulated in HPV-induced cancer.  
Wald et al.29 showed that the presence of the oncogene HPV-16 E6 and E7 results in 
downregulation of miR-181a in human cells. Roles attributed to this miRNA are 
inhibition of virus infection and replication in porcine reproductive and respiratory 
syndrome virus,77 activation of anti-inflammatory pathways,78 a tumour-suppressor role30 
and as a prognostic biomarker in leukaemia patients79 and non-small cell lung cancer 
patients.25 is miRNA has been predicted to be encoded in a chromosomal region that has 
been linked to the development of sarcoids in Warmblood horses.71  
In summary, this is the first report of equine miRNAs that are differentially regulated by 
BPV-1. Future work using high-throughput sequencing will be necessary to verify the 
equine miRNA sequences identified here; however, this study should provide a basis for 
further studies investigating detailed roles of miRNAs in BPV-1-induced transformation 
and in the pathogenesis of ES tumours.  
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